Understand the source comparison
Tolerance to Wolverine Stack Cycling: Administration vs Compounding Comparison
Receptor density at day 21 45–55% of baseline 65–75% of baseline 85–95% of baseline (post-washout) Mesocycle cycling is the only protocol that restores near-baseline receptor availability Observable efficacy decline Noticeable by day 14–18 Moderate by day 28–3
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Receptor density at day 21
- 45–55% of baseline
- 65–75% of baseline
- 85–95% of baseline (post-washout)
- Mesocycle cycling is the only protocol that restores near-baseline receptor availability
- Observable efficacy decline
- Noticeable by day 14–18
- Moderate by day 28–35
- Minimal through week 6, resets after washout
- Continuous administration fails by week 3; microcycles delay but don't prevent tolerance
- Suitable research duration
- ≤ 3 weeks
- 4–8 weeks
- 6–12 months (multiple cycles)
- Only mesocycle protocols support extended timelines without efficacy loss
- Dose escalation required
- By day 21–28
- By day 35–42
- Not required if cycling executed properly
- Dose escalation is a tolerance symptom, not a solution
- Washout period impact
- No recovery mechanism
- Partial recovery (48 hours insufficient)
- Full receptor re-expression (21 days)
- Washout duration below 14 days produces incomplete recovery
- This table reflects observed patterns across research models using BPC-157, TB-500, and Epithalon administered individually or in stack formation. The 6-weeks-on-3-weeks-off mesocycle consistently outperforms both continuous and microcycle-only protocols when measured by sustained biological response across timelines exceeding 12 weeks.